Patents Assigned to Torrey Pines Institute for Molecular Studies
-
Patent number: 11352370Abstract: Compositions and methods for inhibits the binding of GTP to oncogenic mutant KRas are disclosed. These compositions may be used in method to treat a subject with cancer. In particular, the compositions may be used to treat cancers involving overactive Ras signaling.Type: GrantFiled: July 13, 2020Date of Patent: June 7, 2022Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., Torrey Pines Institute for Molecular StudiesInventors: Said M. Sebti, Yangmei Li, Richard A. Houghten
-
Patent number: 11149028Abstract: The invention provides methods for treating cancers, such as melanoma and/or metastatic melanoma, using compounds that interact with and/or inhibit cellular proteins lamin A/C, ATP-dependent RNA helicase DDX1 (DDX1), heterogeneous nuclear ribonuclear protein H1/H2 (hnRNP H2), and/or heterogeneous nuclear ribonuclear protein A2/B1 (hnRNP A2/B1). The invention additionally provides a method for identifying compounds active against melanoma cells.Type: GrantFiled: December 15, 2017Date of Patent: October 19, 2021Assignees: Nova Southeastern University, Auburn University, Florida Atantic University Board Of Trustees, Torrey Pines Institute for Molecular StudiesInventors: Dmitriy Minond, Gregg B. Fields, Marcello Giulianotti
-
Patent number: 11014876Abstract: Cancer is a disease for which there remains a great unmet medical need, and therefore the discovery and development of new antineoplastic agents is critically important. The present invention relates in part to new therapeutic compounds with antineoplastic activity. Provided herein are polyamine sulfonamides such as compounds of Formula (I), or pharmaceutically acceptable salts thereof, which may be used in the treatment and/or prevention of diseases such as cancer. Also provided herein are pharmaceutical compositions and kits comprising the inventive compounds. Furthermore, the present invention provides methods of treating and/or preventing diseases (e.g., cancer) using compounds of Formula (I), or pharmaceutically acceptable salts thereof or pharmaceutical compositions thereof. Other methods provided include methods for inducing apoptosis of a cell, as well as methods for inhibiting alpha-enolase enzymatic activity in vivo and in vitro.Type: GrantFiled: November 4, 2016Date of Patent: May 25, 2021Assignees: University of Florida Research Foundation, Inc., Torrey Pines Institute for Molecular StudiesInventors: Christopher R. Cogle, Amy M. Meacham, Peter P. Sayeski, Marcello A. Giulianotti, Richard A. Houghten, Gregory S. Welmaker
-
Patent number: 10899793Abstract: Certain embodiments of the invention provide a compound of formula (I): R1—C(?O)—W—X—Y—Z—N(R2)2??(I) or a salt thereof, wherein R1, R2, W, X, Y and Z are as defined herein, as well as methods of use thereof.Type: GrantFiled: May 25, 2017Date of Patent: January 26, 2021Assignees: Regents of the University of Minnesota, Torrey Pines Institute for Molecular StudiesInventors: Carrie Haskell-Luevano, Skye Ross Doering, Jon R. Appel, Marc A. Giulianotti, Richard A. Houghten, Clemencia Pinilla, Radleigh G. Santos
-
Patent number: 10711014Abstract: Compositions and methods for inhibits the binding of GTP to oncogenic mutant KRas are disclosed. These compositions may be used in method to treat a subject with cancer. In particular, the compositions may be used to treat cancers involving overactive Ras signaling.Type: GrantFiled: August 14, 2019Date of Patent: July 14, 2020Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., Torrey Pines Institute for Molecular StudiesInventors: Said M. Sebti, Yangmei Li, Richard A. Houghten
-
Publication number: 20200062736Abstract: The invention provides methods for treating cancers, such as melanoma and/or metastatic melanoma, using compounds that interact with and/or inhibit cellular proteins lamin A/C, ATP-dependent RNA helicase DDX1 (DDX1), heterogeneous nuclear ribonuclear protein H1/H2 (hnRNP H2), and/or heterogeneous nuclear ribonuclear protein A2/B1 (hnRNP A2/B1). The invention additionally provides a method for identifying compounds active against melanoma cells.Type: ApplicationFiled: December 15, 2017Publication date: February 27, 2020Applicants: NOVA SOUTHEASTERN UNIVERSITY, AUBURN UNIVERSITY, FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES, TORREY PINES INSTITUTE FOR MOLECULAR STUDIESInventors: Dmitriy Minond, Gregg B. Fields, Marcello Giulianotti
-
Patent number: 10421764Abstract: Compositions and methods for inhibits the binding of GTP to oncogenic mutant KRas are disclosed. These compositions may be used in method to treat a subject with cancer. In particular, the compositions may be used to treat cancers involving overactive Ras signaling.Type: GrantFiled: April 25, 2016Date of Patent: September 24, 2019Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., Torrey Pines Institute for Molecular StudiesInventors: Said M. Sebti, Yangmei Li, Richard A. Houghten
-
Publication number: 20180297942Abstract: Cancer is a disease for which there remains a great unmet medical need, and therefore the discovery and development of new antineoplastic agents is critically important. The present invention relates in part to new therapeutic compounds with antineoplastic activity. Provided herein are polyamine sulfonamides such as compounds of Formula (I), or pharmaceutically acceptable salts thereof, which may be used in the treatment and/or prevention of diseases such as cancer. Also provided herein are pharmaceutical compositions and kits comprising the inventive compounds. Furthermore, the present invention provides methods of treating and/or preventing diseases (e.g., cancer) using compounds of Formula (I), or pharmaceutically acceptable salts thereof or pharmaceutical compositions thereof. Other methods provided include methods for inducing apoptosis of a cell, as well as methods for inhibiting alpha-enolase enzymatic activity in vivo and in vitro.Type: ApplicationFiled: November 4, 2016Publication date: October 18, 2018Applicants: University of Florida Research Foundation, Inc., Torrey Pines Institute for Molecular StudiesInventors: Christopher R. Cogle, Amy M. Meacham, Peter P. Sayeski, Marcello A. Giulianotti, Richard A. Houghten, Gregory S. Welmaker
-
Patent number: 10085981Abstract: Embodiments of the present disclosure include compositions and pharmaceutical compositions that include protein acyl transferases (PAT) inhibitors, methods of treating a condition or disease, methods of treating autopalmitoylation activity, and the like.Type: GrantFiled: July 13, 2016Date of Patent: October 2, 2018Assignees: University of South Florida, Torrey Pines Institute for Molecular StudiesInventors: Robert Joseph Deschenes, Marcello Angelo Giulianotti, Richard Allen Houghten, David Allen Mitchell, Laura Dawn Hamel
-
Patent number: 10052309Abstract: The present disclosure provides compositions including a bis-cyclic guanidine compound, pharmaceutical compositions including a bis-cyclic guanidine compound, methods of treatment of a condition (e.g., bacterial infection) or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.Type: GrantFiled: August 31, 2017Date of Patent: August 21, 2018Assignees: University of South Florida, Torrey Pines Institute for Molecular StudiesInventors: Lindsey Neil Shaw, Renee Marie Fleeman, Richard Allen Houghten, Marcello Angelo Giulianotti, Radleigh G. Santos, Adel Nefzi
-
Patent number: 10048272Abstract: The present invention provides novel methods and assays for high-throughput screening of combinatorial libraries to identify FPR1 and/or FPR2 ligands (e.g., agonists and/or antagonists), preferably FPR1 agonists and/or FPR2 antagonists, by positional scanning deconvolution. The invention also provides novel FPR1 and FPR2 ligands (e.g, agonists and antagonists), related pharmaceutical compositions and methods of treating FPR1 and FPR2-related disorders.Type: GrantFiled: February 2, 2016Date of Patent: August 14, 2018Assignees: STC.UNM, Torrey Pines Institute for Molecular StudiesInventors: Bruce S. Edwards, Larry A. Sklar, Clemencia Pinilla, Richard A. Houghten, Jon R. Appel, Marc A. Giulianotti, Jose Medina-Franco
-
Publication number: 20180200250Abstract: Embodiments of the present disclosure include compositions and pharmaceutical compositions that include protein acyl transferases (PAT) inhibitors, methods of treating a condition or disease, methods of treating autopalmitoylation activity, and the like.Type: ApplicationFiled: July 13, 2016Publication date: July 19, 2018Applicants: University of South Florida, TORREY PINES INSTITUTE FOR MOLECULAR STUDIESInventors: ROBERT JOSEPH DESCHENES, MARCELLO ANGELO GIULIANOTTI, RICHARD ALLEN HOUGHTEN, DAVID ALLEN MITCHELL, LAURA DAWN HAMEL
-
Patent number: 9994536Abstract: Embodiments of the present disclosure provide for compositions including a compound, pharmaceutical compositions including the compound, methods of treatment of a disease or related condition (e.g., neurological disease on condition), methods of treatment using compositions or pharmaceutical compositions, and the like.Type: GrantFiled: May 1, 2015Date of Patent: June 12, 2018Assignee: Torrey Pines Institute for Molecular StudiesInventors: Madepalli K. Lakshmana, Adel Nefzi, Richard Houghten, Dmitriy Minond
-
Patent number: 9988341Abstract: The present invention provides novel compounds as bacterial topoisomerase inhibitors with antibacterial activity. The present invention also provides pharmaceutical compositions comprising at least one of the compounds and methods of using the compounds and pharmaceutical compositions as antibacterial agents for treating infectious diseases.Type: GrantFiled: April 19, 2017Date of Patent: June 5, 2018Assignees: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES, TORREY PINES INSTITUTE FOR MOLECULAR STUDIESInventors: Yuk-Ching Tse-Dinh, Marcello Angelo Giulianotti, Richard Allen Houghten
-
Patent number: 9782388Abstract: The present disclosure provides compositions including a bis-cyclic guanidine compound, pharmaceutical compositions including a bis-cyclic guanidine compound, methods of treatment of a condition {e.g., bacterial infection) or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.Type: GrantFiled: February 19, 2015Date of Patent: October 10, 2017Assignees: University of South Florida, Torrey Pines Institute for Molecular StudiesInventors: Lindsey Neil Shaw, Renee Marie Fleeman, Richard Allen Houghten, Marcello Angelo Giulianotti, Radleigh G. Santos, Adel Nefzi
-
Publication number: 20170121296Abstract: Embodiments of the present disclosure provide for compositions including a compound, pharmaceutical compositions including the compound, methods of treatment of a disease or related condition (e.g., neurological disease on condition), methods of treatment using compositions or pharmaceutical compositions, and the like.Type: ApplicationFiled: May 1, 2015Publication date: May 4, 2017Applicant: TORREY PINES INSTITUTE FOR MOLECULAR STUDIESInventors: MADEPALLI K. LAKSHMANA, ADEL NEFZI, RICHARD HOUGHTEN, DMITRIY MINOND
-
Patent number: 9610351Abstract: Methods and compositions for treating pain are disclosed. The compositions are based on dry powders comprising microparticles of diketopiperazines and an analgesic active agent. The analgesic in the compositions comprises one or more peptide analgesics or derivatives thereof, which are administered to a subject using a pulmonary inhalation drug delivery system comprising a dry powder inhaler and the analgesic composition. The present compositions produce fewer side effects associated with current opioid therapy.Type: GrantFiled: February 13, 2015Date of Patent: April 4, 2017Assignees: MannKind Corporation, TORREY PINES INSTITUTE FOR MOLECULAR STUDIESInventors: Andrea Leone-Bay, Richard A. Houghten, Joseph J. Guarneri, Grayson W. Stowell
-
Publication number: 20160304529Abstract: The present invention relates to opioid compounds, especially to C14 esters and ethers of naltrexone and analogues thereof. The present invention also relates to compositions, methods and medical uses that employ such compounds. More specifically, the present invention pertains to compounds of formula: and to their use in the treatment of diseases and disorders including pain, hyperalgesia, addiction, substance abuse disorders, stress, anorexia, anxiety, depression, cough, asthma, hypertension, gastrointestinal motility disorder, water retention, cognitive disorders, and locomotor disorders.Type: ApplicationFiled: December 5, 2014Publication date: October 20, 2016Applicants: THE UNIVERSITY OF BATH, THE TORREY PINES INSTITUTE FOR MOLECULAR STUDIES, SRI INTERNATIONALInventors: John LEWIS, Stephen HUSBANDS, Lawrence TOLL
-
Patent number: 9310364Abstract: The present invention provides novel methods and assays for high-throughput screening of combinatorial libraries to identify FPR1 and/or FPR2 ligands (e.g., agonists and/or antagonists), preferably FPR1 agonists and/or FPR2 antagonists, by positional scanning deconvolution. The invention also provides novel FPR1 and FPR2 ligands (e.g, agonists and antagonists), related pharmaceutical compositions and methods of treating FPR1 and FPR2-related disorders.Type: GrantFiled: February 6, 2014Date of Patent: April 12, 2016Assignees: STC.UNM, TORREY PINES INSTITUTE FOR MOLECULAR STUDIESInventors: Bruce S. Edwards, Larry A. Sklar, Clemencia Pinilla, Richard A. Houghten, Jon R. Appel, Marc A. Giulianotti, Jose Medina-Franco
-
Patent number: 9233159Abstract: Methods and compositions for treating pain are disclosed. The compositions are based on dry powders comprising microparticles of diketopiperazines and an analgesic active agent. The analgesic in the compositions comprises one or more peptide analgesics or derivatives thereof, which are administered to a subject using a pulmonary inhalation drug delivery system comprising a dry powder inhaler and the analgesic composition. The present compositions produce fewer side effects associated with current opioid therapy.Type: GrantFiled: October 24, 2012Date of Patent: January 12, 2016Assignees: MannKind Corporation, Torrey Pines Institute for Molecular StudiesInventors: Andrea Leone-Bay, Richard A. Houghten, Joseph J. Guarneri, Grayson W. Stowell